
### Reviews

* [Predictive validity in drug discovery: what it is, why it matters and how to improve it](https://www.nature.com/articles/s41573-022-00552-x)
* [Notes on end-to-end biology](https://nintil.com/biology-llms)
* [Machine Learning for Protein Engineering](https://arxiv.org/abs/2305.16634)
* [Inside the nascent industry of AI-designed drugs](https://www.nature.com/articles/s41591-023-02361-0)
* [Tapping into the drug discovery potential of AI](https://www.nature.com/articles/d43747-021-00045-7)


### small molecule- protein structure

* [MISATO - Machine learning dataset for structure-based drug discovery](https://www.biorxiv.org/content/10.1101/2023.05.24.542082v2).  nearly 20,000 experimental structures of protein-ligand complexes + associated properties:

### protein/antibody design

* [Efficient evolution of human antibodies from general protein language models](https://www.nature.com/articles/s41587-023-01763-2) https://twitter.com/ideasbyjin/status/1656640057384501248?s=51&t=sLukUyq0ReWrcwOwgUR_XA

* [De novo design of protein interactions with learned surface fingerprints](https://www.nature.com/articles/s41586-023-05993-x)

* [Large language models generate functional protein sequences across diverse families](https://www.nature.com/articles/s41587-022-01618-2)

* [A billion synthetic 3D-antibody-antigen complexes enable unconstrained machine-learning formalized investigation of antibody specificity prediction](https://www.biorxiv.org/content/10.1101/2021.07.06.451258v3) https://github.com/csi-greifflab/Absolut. Unconstrained lattice antibody-antigen bindings generator - One tool to simulate them all!

* [Generative language modeling for antibody design](https://www.biorxiv.org/content/10.1101/2021.12.13.472419v2) https://twitter.com/jeffruffolo/status/1606058881171406848

* Excited to share our new computational method, APPRAISE, that ranks engineered proteins by how likely they bind to a target. [Fast, accurate ranking of engineered proteins by receptor binding propensity using structural modeling](https://www.biorxiv.org/content/10.1101/2023.01.11.523680v1.full)  https://twitter.com/dingxiaozhe/status/1618257727515676672?s=46&t=f8b5WHByAZFWrIkVXOgyAQ

* [Unlocking de novo antibody design with generative artificial intelligence](https://www.biorxiv.org/content/10.1101/2023.01.08.523187v3)

### we are not there yet?

* https://mobile.twitter.com/SurgeBiswas/status/1613232556673224705
* [AI-driven drug discovery companies, BenevolentAI, recently underwent layoffs and restructuring in response to a PhIIa failure of their atopic dermatitis program](https://decodingbio.substack.com/p/biobyte-032-ai-and-the-overlooked)
* [DeepMind AlphaFold for antibody discovery: What's the status?](https://www.naturalantibody.com/use-case/deepmind-alphafold-for-antibody-discovery-whats-the-status/) Experimental conclusion: We performed a very easy experiment to check if there’s “a free lunch” for antibody discovery employing AlphaFold2. Unfortunately, according to our results, this is not the case"
* Has AI discovered drug? https://www.science.org/content/blog-post/has-ai-discovered-drug-now-guess
* [Why AlphaFold won’t revolutionise drug discovery](https://www.chemistryworld.com/opinion/why-alphafold-wont-revolutionise-drug-discovery/4016051.article)
